Status:
NOT_YET_RECRUITING
Treg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy
Lead Sponsor:
Instituto de Oftalmología Fundación Conde de Valenciana
Conditions:
Conjunctivitis, Allergic
Eligibility:
All Genders
5-30 years
Brief Summary
This study aims to evaluate the effector function and expression of TIGIT and PD-1 on Tregs, as well as the Th2/Treg ratio, in patients with allergic conjunctivitis with and without desensitization th...
Detailed Description
Allergic conjunctivitis is a prevalent ocular condition affecting approximately 10-20% of the global population, with 40-60% of allergic individuals exhibiting ocular symptoms. It is characterized by ...
Eligibility Criteria
Inclusion
- Subjects aged between 5 and 30 years, of either sex.
- Subjects with a confirmed diagnosis of allergic conjunctivitis.
- Presence of active symptoms.
- Positive skin tests.
- Willingness to participate in the protocol by signing informed consent.
Exclusion
- Subjects who have had an infection within the two months prior to sample collection.
- Patients with other active systemic allergic diseases (such as bronchial asthma, dermatitis, among others).
- Subjects with chronic-degenerative or autoimmune diseases.
- Subjects who have received topical immunosuppressive treatment in the last two months.
- Subjects receiving systemic immunosuppressive therapy.
Key Trial Info
Start Date :
January 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07171307
Start Date
January 1 2026
End Date
September 1 2026
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto de Oftalmología FAP Conde de Valenciana, IAP Sede Centro
Mexico City, Mexico City, Mexico, 06800